期刊文献+

静注人免疫球蛋白(pH4)的稳定性研究

Study on the stability of the human immunoglobulin(pH4) for intravenous injection
下载PDF
导出
摘要 目的:考察静注人免疫球蛋白(pH4)的稳定性。方法对三批静注人免疫球蛋白(pH4)进行2~8℃条件下为期3年的长期稳定性试验,对考察的制品依照《中华人民共和国药典》2005年版二部中附录XIX C药物稳定性试验指导原则及《中华人民共和国药典》2010年版二部中附录XIX C原料药及药物制剂稳定性试验指导原则进行检测。结果在长期稳定性试验过程中,可见异物,纯度、pH值、IgG含量、蛋白质含量、分子大小分布等均无明显的变化趋势。结论静注人免疫球蛋白(pH4)稳定性良好,在进行3年长期稳定性试验后,其质量仍符合《中华人民共和国药典》2010年版三部的要求。 Objective Investigate the stability of human immunoglobulin (pH4) for intravenous injection. Methods The three batch of human immunoglobulin(pH4) for intravenous injection were carried on the long term stability test of 3 years in 2~8℃. Tested the inspection product in accordance with the“drug stability test guiding principle”of the Chinese Pharmacopeia(Volume Ⅱ , 2005 edition)in appendix XIX C and“stability principle of raw material medicine and drug"of the Chinese Pharmacopeia(VolumeⅡ, 2010 edition)in appendix XIX C. Results In the long term stability of the test process, visible foreign matter, purity, pH value, IgG content, protein content, molecular size distribution have no obvious variation trend. Conclusion Human immunoglobulin (pH4) for intravenous injection has good stability, after 3 years of long term stability test, the quality is still in accordance with the requirements of Chinese Pharmacopeia(VolumeⅢ, 2010 edition).
出处 《中国实用医药》 2014年第3期27-28,共2页 China Practical Medicine
关键词 静注人免疫球蛋白(pH4) 质量 稳定性 Human immunoglobulin (pH4) for intravenous injection Quality Stability
  • 相关文献

参考文献2

二级参考文献29

  • 1任跃明,程雅琴,倪道明.静脉注射人免疫球蛋白的质量控制[J].中国生物制品学杂志,2005,18(1):73-75. 被引量:12
  • 2王憬惺.静脉注射免疫球蛋白的性质及其临床应用[J].国外医学.输血及血液学分册,1994,17:385-385. 被引量:4
  • 3Cohn E J, Strong LE, Hughes W J, et al. Preparation and properties of serum and plasma proteins IV. A system for the separation into fractions of the protein and lipoprotein components of tissues and fluids[J]. J Am Chem Soc.. 1946, 68,(2):459 -475. 被引量:1
  • 4Imbach P.Barandun S.d'Apuzzo V.et al High-dose imtravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood[J]. Lancet 1981, I :1228 - 1231. 被引量:1
  • 5Sapan CV, Reisener HM, Lundblad RL. Antibody therapy (IVIG) : evaluation of the use of genomics and proteomics for the study of immunomodulation therapeutics[J]. Vox Sanguinis 2007, 92(1) :197 - 205. 被引量:1
  • 6Schroeder DD, Dumas MI. A prepauation of modified immune serum globulin(human) suitable for intravenous administration. Further chtuacterization and comparison with pepsin treated intravenous gamma globulin [ J ]. Am J Med 1984, 76 ( suppl 3A) : 33 - 39. 被引量:1
  • 7Masuho Y, Tomibe K, Matsuzawa K, et al. Development of an intravenous γ-globulin into tile original γ-globulin with Fc activities I . Preparation and characterization of S-sulfonated truman γ-globulin[J]. Vox Sang1977, 32(3) :290-295. 被引量:1
  • 8polson A, Ruiz-bravo C. Fractionation of plasma with polyethylene Glycol[J]. Vox Sang 1972, 23(1) :107 - 118. 被引量:1
  • 9McCue JP, Hein EH, Tenold R. Three generations of immunoglobulin C preparations for clinical use[ J]. Rev intect Dis. 1985, 8 (suppl4) : S374 - S381. 被引量:1
  • 10Mitra G, Wong MF, Mozen MM, et al. Elimination of infectious, retroviruses during preparation of immunoglobulins [ J ]. Transfusion 1986, 26(4) :394 - 397. 被引量:1

共引文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部